公开(公告)号：US20230151103A1

公开(公告)日：2023-05-18

申请号：US17886809

申请日：2022-08-12

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Luciana MOLINERO ,  Sanjeev MARIATHASAN ,  Shannon TURLEY ,  Jillian ASTARITA ,  Rafael CUBAS ,  Yagai YANG

IPC: C07K16/28 ,  C12Q1/6886 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/2866 ,  A61P35/00 ,  C07K16/2827 ,  C12Q1/6886 ,  G01N33/5743 ,  G01N33/57415 ,  G01N33/57492 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/75 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The invention provides methods for identifying an individuals with a disease or disorder who is less likely to respond to immunotherapy alone, the method comprising determining the presence of a stromal gene signature in a sample from the individual, said signature comprising one or more of FAP, FN1, MMP2, PDGFRB, or THY, wherein an increase in the level of expression of the one or more genes in the stroma gene signature relative to a median level identifies an individual for treatment with an immunotherapy and with a suppressive stromal antagonist. In some aspects, the invention provides methods for treating an individual displaying the stromal gene signature. In other aspects, the invention provides kits for determining the presence of a stroma gene signature in a sample from an individual.

公开(公告)号：US20190085087A1

公开(公告)日：2019-03-21

申请号：US16192008

申请日：2018-11-15

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Luciana MOLINERO ,  Sanjeev MARIATHASAN ,  Shannon TURLEY ,  Jillian ASTARITA ,  Rafael CUBAS ,  Yagai YANG

IPC: C07K16/28 ,  G01N33/574 ,  A61P35/00

Abstract: The invention provides methods for identifying an individuals with a disease or disorder who is less likely to respond to immunotherapy alone, the method comprising determining the presence of a stromal gene signature in a sample from the individual, said signature comprising one or more of FAP, FN1, MMP2, PDGFRB, or THY, wherein an increase in the level of expression of the one or more genes in the stroma gene signature relative to a median level identifies an individual for treatment with an immunotherapy and with a suppressive stromal antagonist. In some aspects, the invention provides methods for treating an individual displaying the stromal gene signature. In other aspects, the invention provides kits for determining the presence of a stroma gene signature in a sample from an individual.